A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

ClinicalTrials.gov ID: NCT06172478

Public ClinicalTrials.gov record NCT06172478. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric cancer ovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, prostate cancer, second-line gastric cancer, lung cancer, and breast cancer.

Study identification

NCT ID: NCT06172478
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Daiichi Sankyo; Industry
Enrollment: 740 participants

Conditions and interventions

Conditions

Interventions

HER3-DXd Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 26, 2024 (Actual)
Primary completion: Sep 1, 2027 (Estimated)
Completion: Oct 10, 2028 (Estimated)
Last update posted: Oct 1, 2026

2024 – 2028

United States locations

U.S. sites: 13
U.S. states: 11
U.S. cities: 13

Facility	City	State	ZIP	Site status
City of Hope	Duarte	California	91010	Recruiting
Yale Cancer Center	New Haven	Connecticut	06510	Recruiting
AdventHealth Medical Group Oncology Research at Celebration	Kissimmee	Florida	34747	Recruiting
University of Illinois Cancer Center	Chicago	Illinois	60612	Recruiting
Johns Hopkins University	Baltimore	Maryland	21205	Recruiting
Health Partners Frauenshuh Cancer Center	Saint Louis Park	Minnesota	55426	Recruiting
Health Partners Cancer Center at Regions Hospital	Saint Paul	Minnesota	55101	Recruiting
Washington University, School of Medicine	St Louis	Missouri	63110	Recruiting
Roswell Park Cancer Institute IDS	Buffalo	New York	14203	Recruiting
Memorial Sloan Kettering Hospital	New York	New York	10065	Recruiting
SCRI Oncology Partners	Nashville	Tennessee	37203	Recruiting
The University of Texas MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
Fred Hutchinson Cancer Center	Seattle	Washington	98109	Completed

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 81 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06172478, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 1, 2026 · Synced Oct 16, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06172478 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →